このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

VITA 34 マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Jakub Baran

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	3.9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Jakub Baran

2.3yrs

在職期間

Mr. Jakub Julian Baran serves as Chairman of the Management Board and Chief Executive Officer at VITA 34 AG since March 22, 2022. He serves as Member of the Supervisory Board at Betacom S.A. since May 2019...

取締役

名称	ポジション	在職期間	報酬	所有権
Isadore Ances	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
A. Bader	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
Robert Iannone	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
W. Holzgreve	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
Carlo Croce	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
Jack Goldberg	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
E. Wunder	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
Ronald Wapner	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
Zbigniew Mrowiec	Member of Scientific & Medical Advisory Board	no data	データなし	データなし
Florian Schuhbauer	Deputy Chairman of the Supervisory Board	3.9yrs	€20.00k	データなし
Alexander Granderath	Chairman of Supervisory Board	2.5yrs	データなし	データなし
Frank Kohler	Independent Member of the Supervisory Board	7yrs	€30.00k	データなし

3.9yrs

平均在職期間

経験豊富なボード: V3Vの取締役会は経験豊富であると考えられます ( 3.9年の平均在任期間)。

VITA 34 マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

VITA 34 AG, Annual General Meeting, Jun 29, 2022

VITA 34 AG, Annual General Meeting, Jun 30, 2021

Recent updates

First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Price target increased by 15% to €6.00

No longer forecast to breakeven

VITA 34 AG to Report Q1, 2024 Results on May 31, 2024

New minor risk - Share price stability

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)

Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)

New minor risk - Share price stability

New minor risk - Market cap size

First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)

Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate

Full year 2022 earnings released: €1.71 loss per share (vs €0.63 loss in FY 2021)

VITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023

Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)

Price target decreased to €10.50

Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)

VITA 34 AG Revises Earnings Guidance for the Financial Year 2022

VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022

VITA 34 AG, Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VITA 34 AG to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022

Price target increased to €25.00

Price target increased to €21.10

Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)

Second quarter 2021 earnings released

VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.

VITA 34 AG Provides Earnings Guidance for the Year 2021

First quarter 2021 earnings released

Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)

VITA 34 AG to Report Q1, 2021 Results on May 11, 2021

New 90-day high: €14.05

New 90-day high: €13.00

VITA 34 AG, Annual General Meeting, Jun 30, 2021

Price target raised to €17.50

Third quarter 2020 earnings released: EPS €0.18

Revenue and earnings miss expectations

New 90-day low: €11.15

Earnings released

VITA 34 AG to Report Q2, 2020 Results on Aug 27, 2020

New 90-day low - €11.60

AOC Health GmbH acquired a 27.3% stake in VITA 34 AG (XTRA:V3V).

CEO（最高経営責任者

在職期間

取締役

平均在職期間

マネジメント基準チェック /14